EU/3/18/2043

About

On 31 July 2018, orphan designation (EU/3/18/2043) was granted by the European Commission to Dr Ulrich Granzer, Germany, for combination of carboplatin and sodium valproate for the treatment of glioma.

Key facts

Active substance
Combination of carboplatin and sodium valproate
Disease / condition
Treatment of glioma
Date of decision
31/07/2018
Outcome
Positive
Orphan decision number
EU/3/18/2043

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Dr Ulrich Granzer
Mauerkircherstrasse 105
81925 Munich
Germany
Tel. +49 8978 0689820
Fax +49 8978 0689815
E-mail: granzer@granzer.biz

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating